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New CNS neurons and glia are generated throughout adulthood from endogenous neural stem and progenitor cells. These progenitors
can respond to injury, but their ability to proliferate, migrate, differentiate, and survive is usually insufficient to replace lost cells and
restore normal function. Potentiating the progenitor response with exogenous factors is an attractive strategy for the treatment of
nervous system injuries and neurodegenerative and demyelinating disorders. Previously, we reported that delivery of leukemia inhibi-
tory factor (LIF) to the CNS stimulates the self-renewal of neural stem cells and the proliferation of parenchymal glial progenitors. Here
we identify these parenchymal glia as oligodendrocyte (OL) progenitor cells (OPCs) and show that LIF delivery stimulates their prolifer-
ation through the activation of gp130 receptor signaling within these cells. Importantly, this effect of LIF on OPC proliferation can be
harnessed to enhance the generation of OLs that express myelin proteins and reform nodes of Ranvier in the context of chronic demy-
elination in the adult mouse hippocampus. Our findings, considered together with the known beneficial effects of LIF on OL and neuron
survival, suggest that LIF has both reparative and protective activities that make it a promising potential therapy for CNS demyelinating
disorders and injuries.
Introduction
Oligodendrocytes (OLs) wrap axons in myelin, coordinate ion
channel clustering at nodes of Ranvier, and provide trophic sup-
port for axons. Consequently, the OL loss that occurs in the le-
sions of demyelinating disorders such as multiple sclerosis (MS)
and after traumatic CNS injury contributes to ongoing disability.
Remyelination of these lesions by endogenous OL progenitor
cells (OPCs) occurs in animal models and some patients but is
variable and insufficient. One approach to enhance remyelina-
tion is to administer factors that can mobilize endogenous OPCs
and neural stem cells (NSCs) and direct their differentiation into
OLs. In this regard, several of the neuropoietic, gp130 cytokines,
most notably leukemia inhibitory factor (LIF) and ciliary neu-
rotrophic factor (CNTF), havemultiple activities thatmake them
attractive therapeutic candidates. First, in culture, LIF and CNTF
enhance the proliferation of OPCs (Barres et al., 1996). Second,
LIF and CNTF promote the maturation of cultured OPCs into
OLs (Mayer et al., 1994), and inmixed hippocampal cultures, the
release of LIF by astrocytes stimulates myelination (Ishibashi et
al., 2006). Third, after injury, LIF activates astrocytes and micro-
glia (Sugiura et al., 2000; Kerr and Patterson, 2004), cell types that
can modulate disease by limiting the spread of the lesion and
clearing myelin debris, respectively, and produce cytokines and
growth factors critical for remyelination (Arnett et al., 2001; Ma-
son et al., 2001; Hendriks et al., 2008; Haroon et al., 2011).
Fourth, axon regrowth after optic nerve crush is enhanced by
inflammation through a process that requires CNTF and LIF
(Leibinger et al., 2009). Fifth, LIF stimulates the self-renewal of
adult NSCs in the subventricular zone (SVZ), which may expand
this population to facilitate repair (Bauer and Patterson, 2006).
This finding has relevance for the repair of demyelination since
NSCs can generate migratory OPCs that differentiate into OLs
and contribute to remyelination (Menn et al., 2006). Finally, sev-
eral gp130 cytokines also enhance the survival of OLs in culture
(Louis et al., 1993; Mayer et al., 1994; Barres et al., 1996; Zhang et
al., 2006) and in models of spinal cord injury and MS (Butzkue-
ven et al., 2002; Kerr et al., 2005; Marriott et al., 2008).
Whereas the protective effects of LIF on OLs are well de-
scribed, it is not clear that LIF delivery can enhance the endoge-
nous remyelination response. Since LIF not only stimulates OPC
proliferation and OL generation in vitro, but also acts on micro-
glia and astrocytes, we hypothesized that supplying exogenous
LIF could provide the necessary signals to expand the population
of OPCs in demyelinated lesions and promote their differentia-
tion intomyelinatingOLs. To test this hypothesis, we chose to use
the cuprizone model of demyelination in a proof-of-concept ex-
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periment. Cuprizone induces a time course of demyelination and
remyelination that is well characterized and reproducible in re-
gional impact and severity, and it allows for testing potential
remyelination-promoting paradigms at times when OLs have
been almost completely ablated. This provides for a clear inter-
pretation of themechanism underlying any observed therapeutic
benefit (i.e., that it is attributable to enhanced remyelination
rather than protection of existing OLs), a distinction that is crit-
ical for evaluating the potential remyelination-promoting effects
of LIF and dissociating these effects from its pro-survival effects
on OLs.
Materials andMethods
Animals. C57BL/6J, Rosa-YFP (Srinivas et al., 2001), and Ng2-Cre BAC
(Zhu et al., 2008) transgenic mice were obtained from The Jackson Lab-
oratory. The gp130 fl mice (Betz et al., 1998) and PDGFR-CreER BAC
transgenic mice (Rivers et al., 2008) were generous gifts fromW. Muller
(University of Manchester, Manchester, UK) andW. Richardson (Wolfson
Institute for Biomedical Research, University College London, London,
UK), respectively. The gp130fl;Ng2-Cre and PDGFR-CreER;Rosa-YFP
micewereonmixedbackgrounds:C57BL/6;FVBandCBA;C57BL/6, respec-
tively. Littermates, both male and female, were used for all studies in genet-
ically modified mice. Primer sequences for genotyping are available on
request. All procedures were approved by the California Institute of Tech-
nology Institutional Animal Care and Use Committee.
Adenovirus injection.Recombinant adenovirus,2.7 106 pfu in 3l
(Zhu et al., 2001), encoding mouse LIF (Ad-LIF) or LacZ (Ad-LacZ) was
injected into the lateral ventricle as described (Bauer and Patterson,
2006). This method primarily infects ependymal cells (Doetsch et al.,
1999; Bauer and Patterson, 2006). Five to six mice were used per virus-
injected group for cuprizone experiments, and two to three mice were
used per group for Ad-LIF-induced proliferation assays.
Bromodeoxyuridine and tamoxifen administration. Bromodeoxyuri-
dine (BrdU; Sigma-Aldrich) for injection was made at 10 mg/ml in 0.9%
NaCl and sterile filtered.Mice were given intraperitoneal injections of 50
mg/kg BrdU at the indicated times before they were killed. For long-term
BrdU labeling, BrdU was dissolved in H2O at a concentration of 0.8
mg/ml, sterile filtered, aliquoted, and stored at20°C.Water containing
BrdU was changed daily. Tamoxifen was dissolved by sonication in sun-
flower oil. Mice were given 4 mg of tamoxifen by a single daily intraperi-
toneal injection for 3 consecutive days.
Cuprizone treatment. Eight-week-old C57BL/6J mice from The Jack-
son Laboratory were fed a diet containing 0.2% cuprizone (Sigma-
Aldrich), which was freshly prepared and mixed into milled chow (5001
Rodent Diet; Lab Diet) three times per week. After cuprizone treatment,
mice were returned to a standard pellet chow.
Tissue processing and immunostaining. Mice were anesthetized with
Nembutal and transcardially perfused first with 0.1 M phosphate buffer
(PB), pH 7.4 (room temperature) and then with freshly prepared 4%
paraformaldehyde in PB (4°C). Brains were postfixed for 4–5 h for cry-
ostat sectioning (cuprizone experiments) or overnight for vibratome sec-
tioning (experiments in Fig. 1E–H, 4). For cryostat sectioning, brains
were placed in 4°C PB overnight followed by 24 h of immersion in 20%
sucrose in PB. The brains were then frozen in OCT (Sakura Tissue-
Tek) and stored at80°C until sectioning. Fourteen-micrometer cor-
onal sections were cut on a cryostat (Leica), dried overnight at room
temperature, and stored at 20°C. Floating coronal vibratome sec-
tions were cut at 50 m, collected in PB containing 0.02% sodium
azide, and stored at 4°C.
Immunostaining was performed by diluting primary and secondary
antibodies in PBS containing 10%goat or donkey serumand0.1%Triton
X-100 (frozen sections) or 0.5% Triton X-100 (floating sections). Pri-
mary antibodies used were rat anti-BrdU* (1:250; Oxford Biotechnology
or Abcam), mouse anti-CC1 (1:200; Calbiochem), rabbit anti-GFAP (1:
1000; Dako), rabbit anti-GFP (1:1000; Invitrogen), chicken anti-GFP
(1:2000; Abcam), rabbit anti-Iba1 (1:500; Biocare Medical), mouse anti-
KV1.2* (1:1000; NeuromAb), mouse anti-NaV1.6* (1:500; Alamone
Labs), mouse anti-neurofilament (NF)* (1:50, clone 2H3; Developmen-
tal Studies Hybridoma Bank), rabbit anti-Ng2 (1:300; Millipore), goat
anti-Olig2 (1:500; R & D Systems), mouse anti-proteolipid protein
(PLP)* (1:500; Millipore), mouse anti-Rip (1:50; Developmental Studies
Hybridoma Bank), and rabbit anti-pSTAT3-Y705* (1:500; Cell Signaling
Technology). Primary antibody incubations were performed at room
temperature overnight (slide-mounted sections) and for 2–3 d at 4°C
(floating sections). Several antigens (marked above with an asterisk) re-
quired an antigen unmasking pretreatment. For frozen sections, this was
performed by incubating slides at 100°C for 30min with a pH 6 unmask-
ing agent (Dako) before proceeding with primary antibody incubation.
For floating sections, unmasking the BrdU and pSTAT3 antigens re-
quired pretreatment with 0.1N HCl at 4°C for 30 min followed by im-
mersion in 2NHCl at 37°C for 30 min. Goat or donkey anti-species- and
isotype-specific antibodies conjugated to Alexa-488, 568, or 633 (Invit-
rogen) were incubated with tissue sections for 1–2 h (frozen sections) or
overnight (floating sections). The Rip andNF antibodies were developed
by S. Hockfield (Massachusetts Institute of Technology, Cambridge,
MA) and T. Jessell (Columbia University, New York, NY), respectively,
and were obtained from the Developmental Studies Hybridoma Bank
(dshb@uiowa.edu).
Image analysis and quantification. Slide-mounted sections were im-
aged using a TCS SP confocal microscope (Leica) equipped with argon,
krypton, and He/Ne lasers. Care was taken to sample sections at similar
anatomical levels. For cuprizone studies, cell counts were made from
confocal images taken of coronal sections of the medial CC (0.6 to 0.8
mm caudal to bregma) and the dorsal hippocampus (1.5 to1.9 mm
caudal to bregma). For the experiment shown in Figure 5, BrdU cells
were counted in images of the fimbria between0.7 and1.6 mm.
PLP and NF staining quantification was performed on 63, 10 m
projection images of the CA3 stratum radiatum (medial to the lateral
extent of the mossy fibers) of the hippocampus. A manual threshold,
equivalent for all images, was set in ImageJ (http://rsb.info.nih.gov/ij/)
for each channel, and the area above that threshold was quantified. The
percentage area over threshold for PLP was then divided by the percent-
age area over threshold for NF and presented as a ratio. All values were
normalized to those of the untreated group. Nodes were counted from
images of the CA3 stratum radiatum. The number of NaV1.6
 nodes,
flanked on both sides by Caspr paranodes, was counted in 7 m con-
focal projections images taken with a 63 objective. Adobe Photoshop
CS3 was used to adjust image contrast and brightness (any adjustments
made were made equally for all images within an experiment).
Statistical analysis. Differences between group means were tested for
statistical significance using an unpaired, two-tailed Student’s t test (two
groups) or with a one-way ANOVA and Tukey’s multiple comparison
test (three ormore comparisons). All data are presented asmean SEM.
Analyses were performed using Prism 4.0b software.
Results
LIF promotes OPC proliferation in vivo
In previous work from our group, Bauer et al. (2006) demonstrated
that delivery of exogenous LIF using an adenovirus encoding a se-
creted form of mouse LIF (Ad-LIF) increases the number of prolif-
erating parenchymal glial progenitors expressing Olig2 or S100
threefold to fivefold over the controls that received a-galactosidase
(LacZ)-encoding virus. Because the primary adult glial progenitor
cell population that proliferates outside of the neurogenic niches
are Olig2 OPCs (Nishiyama, 2007), this finding suggested that
LIF delivery stimulates the proliferation and/or generation of this
population. However, whereas Olig2 expression is typically re-
stricted to the OL lineage, it is also expressed by a subset of astro-
cytes during development and after injury (Cai et al., 2007;
Tatsumi et al., 2008), and S100 can be expressed by astrocytes,
OPCs, and myelinating OLs (Rickmann, 1995; Hachem et al.,
2005). Therefore, we sought to further clarify the identity of the
proliferating glia.
Adult OPCs are typically defined and identified by their ex-
pression of Ng2 and platelet-derived growth factor receptor 
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(PDGFR). Three days after intracerebroventricular injection of
Ad-LIF, we found that 41.0 2.7% (mean SEM; n 2) of the
BrdU cells proliferating outside of the SVZ are Ng2 (Fig. 1A).
Nearly all of the proliferating cells not labeled with antibodies di-
rected against Ng2 or Olig2 are Iba1microglia (55.7 4.0% non-
SVZ BrdU cells; mean  SEM; n  2) (Fig. 1B), a finding
consistentwith the previous observation that LIF inducesmicroglial
proliferation (Kerr and Patterson, 2004). LIF signaling activates the
transcription factor STAT3, and in periventricular areas where
STAT3 activation is greatest, we detect activated, phosphorylated
STAT3 in 86.5 2.5%of the proliferatingOlig2OPCs, suggesting
that these cells respond directly to LIF (Fig. 1C). Although LIF
strongly increases STAT3 activation and GFAP expression in astro-
cytes, GFAP cells outside of the SVZ rarely proliferate in response
to acute LIF treatment (Fig. 1D). In line with this finding that most
of theBrdUneuralparenchymalcells inLIF-treatedmiceareOPCs
andnotastrocytes, triple staining forS100,Olig2, andBrdUconfirms
that theBrdU/S100 andBrdU/Olig2populationswepreviously
describedarenearly completelyoverlapping (datanot shown), suggest-
ingthat thesubsetof S100 cells that incorporate BrdU in response
to LIF are Olig2 OPCs.
We next asked whether the stimulation of OPC proliferation by
LIF expands the pool of OPCs. To test this, we used PDGFR-
CreER;ROSA-YFP mice (Rivers et al., 2008), which allow for
tamoxifen-inducible cre-dependent expression of the yellow fluo-
rescent protein (YFP) reporter in PDGFROPCs and their prog-
eny. YFP expression was induced in OPCs by tamoxifen
administration, andmicewere given injections of either Ad-LIF or
Ad-LacZ. Three weeks later, we found that the population of
YFP cells is dramatically expanded in the periventricular re-
gions of Ad-LIF-treated animals compared with control animals
receiving Ad-LacZ (Fig. 1E–I). The vast majority of the YFP
cells are Olig2 in both Ad-LIF- and Ad-LacZ-treated mice
(97.2 0.4 and 98.5 0.6%, respectively, in the dorsal forebrain;
n  3 per group; Fig. 1G,H). We observe occasional YFP cells
with neuronal and pericyte morphology, as has been reported
after tamoxifen injection in this line (Rivers et al., 2008).
LIF restores OL number after demyelination
To examine whether exogenous LIF treatment can enhance the
generation of OLs after cuprizone-induced demyelination, we
treated 8-week-old adult C57BL/6 mice with a cuprizone-
supplemented diet for 5 weeks, delivered Ad-LIF or Ad-LacZ by
intracerebroventricular injection, and returned the mice to a
standard diet. To label cells that proliferate after treatment, we
administered BrdU in the drinking water for a total of 7 d, start-
ing 3 d after virus injection. Twenty-eight days after ceasing cu-
prizone treatment and injecting Ad-LIF or Ad-LacZ (18 d after
removing BrdU from the drinking water), we assessed the num-
ber of newly generated BrdU OLs with and without LIF treat-
ment (Fig. 2B). Remarkably, compared with controls, LIF
increases the number of mature BrdU/CC1 OLs in both the
Figure 1. Exogenous LIF stimulates OPC proliferation. To identify cells responding to acute LIF,
micewere treatedwithAd-LIF andgiven injections of BrdU3and6hbefore theywere killed. Images
showcharacterizationofBrdU cells (green)by immunostaining.A,ManyBrdU cells, highlighted
by arrows, also display staining for both Olig2 (blue) and Ng2 (red). Asterisks highlight BrdU cells
unlabeled by either of these OPC markers. B, Olig2-negative BrdU cells are mostly Iba1 (red)
microglia (arrows).C,Ad-LIFtreatment inducesStat3activation(phospho-Y705Stat3-specific immu-
nostaining; blue) inOlig2/BrdUOPCs (arrows). The cell highlighted in thedashedbox is positive
for BrdU (green), Olig2 (red), and pSTAT3 (blue) immunostaining, as can be seen from the enlarged
individual channel images shown to the right of the tricolor image.D, LIF induces STAT3 phosphory-
lation (blue) inGFAP astrocytes (red), but these cells rarely incorporateBrdU (green) in response to
4
LIF. E–I, Ad-LIF expands the OPC pool. PDGFR-CreER/;ROSA-YFP/micewere induced
with tamoxifen, treated 1 week later with Ad-LacZ (E, G) or Ad-LIF (F, H ), and killed 3 weeks
after adenovirus injection. E, F, Immunostaining for the YFP reporter is shown in green. Dotted
lines outline the lateral ventricle (LV) walls. cc, Corpus callosum; st, striatum; sep, septum. G, H,
Representative images are shown of immunostaining for Olig2 (purple) and YFP (green) in the CC of
Ad-LacZ-treated (G) and Ad-LIF-treated (H ) mice. Scale bars: A–D, G, H, 20m; E, F, 200m. I,
Quantification of the fold increase in YFP/Olig2 cells in periventricular regions of the corpus cal-
losum (cc), striatum (str), hippocampus (hip), fimbria (fimb), and ventral cortex (v cx). **p 0.01;
***p 0.001. The effect of LIF is not significant in the ventral cortex.
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hippocampus and the corpus callosum (CC) by 11.5-fold (105
6.05 BrdU/CC1 cells/mm2 in LIF-treated animals vs 9.2 2.6
in LacZ-treated animals; p  0.001) and 2.5-fold (491  57.1
BrdU/CC1 cells/mm2 in LIF-treated animals vs 196 62.2 in
LacZ-treated animals; p 0.01), respectively. LIF treatment also
increases the percentage ofCC1 cells that are BrdUby 4.6-fold
(44.4  3.5% in LIF-treated animals vs 9.6  2.4% in LacZ-
treated animals; p  0.001) in the hippocampus and 2.3-fold
(16.5  1.9% in LIF-treated animals vs 7.1  2.1% in LacZ-
treated animals; p 0.01) in the CC. This results in a recovery of
CC1 OLs in the hippocampus to a level that is significantly
greater than that seen in the control, LacZ-treated animals (Fig.
2C). In contrast, the number of CC1 OLs in the medial CC,
where the spontaneous regeneration of OLs is much greater, is
not significantly different between Ad-LIF- and Ad-LacZ-treated
animals (2998  114 vs 2673  164 CC1 cells/mm2, respec-
tively; p  0.05). In gray matter (GM) areas such as the hip-
pocampus and cortex, where individual myelinated axons are
more easily discernible, we observe Rip OLs derived from
OPCs, which had proliferated early during LIF treatment, mak-
ing extended contact along axons (Fig. 2D).
These findings demonstrate that LIF dramatically enhances
the generation of OLs in both graymatter and whitematter tracts
after demyelination. Assessing the effect of LIF on remyelination
in these mice is, however, complicated by the significant sponta-
neous remyelination that occurs in the CC and, to a lesser extent,
in the hippocampus, after 5 week cuprizone
treatment. In contrast to 5–6week cuprizone
treatment, spontaneous remyelination has
been reported to be limited after long-term,
12–16 week treatment with cuprizone. The
lack of remyelination after long-term cupri-
zone treatment has been attributed to a re-
duction in OPCs (Mason et al., 2004) and
inhibition by fibroblast growth factor 2
(FGF2) (Armstrong et al., 2002; Armstrong
et al., 2006). Therefore, we next tested
whether LIF treatment would stimulate OPC
proliferation, OL generation, and remyelina-
tion under conditions where OL generation
and remyelination are otherwise impaired.
For this experiment, we treatedmicewith cu-
prizone for 12 weeks (Fig. 3A). Similar to a 5
week course of cuprizone, we found that a 12
week course of cuprizone induces a near-
complete loss of mature OLs and myelin
from the dorsal hippocampus (Fig. 3E and
data not shown). We first assessed whether
OPCs remaining after 12 weeks of cuprizone
treatment still respond to LIF with increased
proliferation. Ad-LIF or Ad-LacZ was deliv-
ered to mice after a 12 week course of cupri-
zone, and the mice were returned to their
standard diet and allowed to recover for 3
weeks. At the end of this recovery period, we
administered BrdU by intraperitoneal injec-
tion 2 and 4 h before the mice were killed to
label proliferating cells. The number of pro-
liferatingOlig2 cells is increased by 3.9-fold
over controls after LIF treatment in the hip-
pocampus (Fig. 3B,C) as is the percentage of
Olig2 cells that are BrdU (3.8  0.2% vs
1.3  0.3% in Ad-LIF- vs Ad-LacZ-treated
animals; p  0.001). A similar trend is observed with LIF treat-
ment in the CC (Fig. 3D), but this does not reach significance.
Therefore, even in the context of chronic demyelination, LIF en-
hances the endogenous progenitor response, at least in the hip-
pocampuswhere there is less spontaneousOPCproliferation.We
next examined whether LIF treatment would promote the gener-
ation ofmature OLs after long-term demyelination. Indeed, after
3 weeks of recovery, the number of CC1OLs in the hippocam-
pus is increased in LIF-treated mice compared with Ad-LacZ-
treated mice (Fig. 3E). Remarkably, after 6 weeks of recovery, the
number of OLs is restored to near-normal numbers in LIF-
treated mice, whereas in stark contrast, little recovery is observed
in mice that receive the control LacZ virus (Fig. 3E). Unlike what
we observe in the hippocampus, the number of OLs in themedial
CC recovers to near that seen in untreated mice even in the ab-
sence of LIF treatment (Fig. 3F). Thus, the spontaneous OL gen-
eration that occurs in the CC obscures any beneficial effect of LIF
that may occur in this region.
LIF treatment promotes remyelination
Based on our encouraging findings in the hippocampus, and our
finding that long-term, 12 week cuprizone treatment completely
abolishes myelin throughout the dorsal hippocampus, as judged
by the loss of PLP immunostaining (Fig. 4B, I), we next sought to
assess the extent of remyelination in the hippocampus. To do
this, we performed immunostaining for PLP together with a NF
Figure 2. LIF enhances OL generation after acute demyelination. Male C57BL/6 mice were fed cuprizone for 5 weeks,
returned to a standard diet, and given an injection of Ad-LIF or Ad-LacZ. Three days after virus injection, BrdUwas supplied in
the drinking water for 7 d, and newly generated OLs were assessed 4 weeks after virus injection. A, A schematic provides an
overviewof the experimental design. i.c.v. inj., Intracerebroventricular injection.B, LIF delivery increases the number of newly
generated BrdU/CC1 OLs in the hippocampus compared with Ad-LacZ controls. Representative images are shown of
immunostaining of the hippocampi (CA3 region) of mice treated as indicated. BrdU (green)/CC1 (purple) OLs are high-
lighted by arrows. Quantification of BrdU/CC1 cells is provided in the text. C, Quantification of the total number of CC1
cells in the CA3 region of the hippocampus. ***p 0.001. The difference between the 54wAd-LacZ group and the 5week
group is not significant ( p 0.05).D, An example of immunostaining for BrdU (green), themature OL protein RIP (red), and
axons (NF; blue) is shown for the hippocampus of an Ad-LIF-treated mouse. Scale bars, 20m.
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antibody to label axons. We chose PLP because its expression is
restricted to compact myelin, with little to no staining in cell
bodies and proximal processes. Because the density ofmyelinated
axons within the hippocampus varies by layer, for consistency we
limited our assessment to the stratum radiatum of the CA3 sub-
field justmedial to the unmyelinatedmossy fibers (Fig. 4A–D, I).
PLP staining was normalized to NF staining to control for any
differences in axon density and minor variations in staining in-
tensities in individual images. Remarkably, after 6 weeks of re-
covery with Ad-LIF, PLP expression is restored to levels
comparable to those observed inmice not treated with cuprizone
(Fig. 4D, I), whereas cuprizone-treatedmice given the LacZ virus
exhibit little recovery in PLP expression (Fig. 4C,I). LIF treat-
ment also enhances the recovery of PLP expression in the stratum
oriens, but interestingly, perforant pathway axons from the en-
torhinal cortex remyelinate spontaneously, even in the absence of
LIF treatment. Likewise, any LIF-dependent myelination of cal-
losal axons that occurred was obscured by spontaneous remyeli-
nation (data not shown).
LIF restores the formation of nodes of Ranvier
Functional recovery of saltatory conductance is dependent on the
formation of nodes of Ranvier. To investigate whether the Ad-
LIF-induced enhancement of PLP expression is associated with
reformation of nodes of Ranvier, we immunostained for the so-
dium channel Nav1.6, which clusters at nodes, as well as the para-
nodal protein Caspr and the Kv1.2 voltage-gated potassium
channel subunit, which clusters in juxtaparanodes. In accordance
with the complete loss of OLs and myelin protein expression in
the hippocampus after cuprizone treatment, the clustering of
Nav1.6 channels, Kv1.2 channels, and the paranodal protein
Caspr within axons of the hippocampus is fully disrupted after 12
weeks of cuprizone exposure (Fig. 4E,F,J). Although scattered
nodes return after 6 weeks in Ad-LacZ-injected mice, mice re-
ceiving Ad-LIF treatment display a highly significant increase in
the number of Nav1.6
 nodes flanked by Caspr paranodes
compared with both 12 week cuprizone- and control Ad-LacZ-
treated mice (Fig. 4F–H, J). Clustered Kv1.2 channels can also be
detected flankingmany, but not all, Caspr paranodes. Since the
accumulation of potassium channels at juxtaparanodes requires
compactmyelin andnot just axon–OL contact (Baba et al., 1999),
this also suggests that Ad-LIF treatment restores compact myelin
and the potential for saltatory conductance in axons within the
stratum radiatum. Therefore, in mice treated with Ad-LIF, newly
generated myelinating OLs restore the clustering of axonal so-
dium and potassium channels as well as axonal–glial paranodal
complexes.
We see a similar LIF-induced increase in PLP OL processes
and Caspr clustering in the stratum oriens lateral to the CA3
pyramidal cell layer, but, interestingly, in this region, Nav1.6 ex-
pression is not detectable between many of the paranodes. Caspr
clustering is known to be dependent on OL contact and expres-
sion of the paranodal OL protein NF155, and we find that NF155
clustering occurs at all sites of axonal Caspr clustering (data not
shown). It is not clear whether the lack of Nav1.6 channels results
from an axo-glial contact on dystrophic axons that fail to cluster
Nav1.6 channels in response to paranodal junctional formation,
or whether the proximity of the lateral stratum oriens to the
ventricle and presumably higher LIF concentration drives abnor-
mal axo-glial paranodal junctional complex formation. In sup-
A C E
D F
B
Figure 3. LIF stimulates OPC proliferation and OL generation in the chronically demyelinated hippocampus. Mice were fed cuprizone for 12 weeks, returned to a standard diet, given injections
of Ad-LIF or Ad-LacZ, and assessed 3 or 6weeks later, as indicated. BrdUwas injected 2 and 4 h before themicewere killed.A, A schematic provides an overviewof the experimental design. i.c.v. inj.,
Intracerebroventricular injection.B, C, LIF increases the number of Olig2/BrdU cells in the hippocampus after 3weeks of recovery.B, Representative images showing immunostaining for Olig2
(purple) and BrdU (green) in the hippocampi of mice treated as indicated. Arrows highlight BrdU/Olig2 cells. C,D, Quantification of Olig2/BrdU cells in the CA3 region of the hippocampus
(C) and themedial CC (D) *p 0.05; **p 0.01. E, F, LIF treatment increases the total number of CC1 OLs in the demyelinated hippocampus but not themedial CC. Quantification of CC1 OLs
in the CA3 region of the hippocampus (E) andmedial CC (F ). In E, ***p 0.001 between 123wAd-LIF and all other groups and between 126wAd-LIF and all groups, other than the untreated
group where p 0.05. In F, *p 0.05 between 12 week and untreated and both 126w groups. Scale bar, 20m.
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port of this later possibility, high doses of LIF are disruptive to
myelination in culture, whereas lower doses enhancemyelination
(Ishibashi et al., 2006).
LIF-stimulated OPC proliferation requires gp130 signaling
within OPCs
We next sought to determine whether the effects of exogenous
LIF treatment onOPC proliferation occur through the activation
of gp130 receptor signaling in these cells. STAT3 is activated
downstream of LIF/gp130 signaling, and
we detect the presence of activated, phos-
phorylated STAT3 in multiple cell types,
including astrocytes, microglia, and pro-
liferating OPCs, responding to exogenous
LIF (Fig. 1C,D; and data not shown). Since
LIF and the related cytokine CNTF en-
hance the proliferation rate of purified
OPCs in the presence of PDGF (Barres et
al., 1996), the in vivo effect of LIF on OPC
proliferationmay, likewise, occur through
direct stimulation of these cells. Alterna-
tively, LIF also has effects on other cell
types, including astrocytes, microglia,
and endothelial cells, all of which can
produce factors that stimulate OPC pro-
liferation (Arnett et al., 2001; Albrecht et
al., 2003, 2007; Arai and Lo, 2009).
Therefore, it is plausible that such cells
indirectly mediate the effect of LIF on
OPC proliferation. To distinguish be-
tween these possible mechanisms, we
asked whether OPCs continue to prolif-
erate in response to LIF after they are ren-
dered insensitive to direct LIF signaling.
For this purpose, we conditionally inacti-
vated the gp130 signaling subunit of the
LIF receptor inOL lineage cells by crossing
gp130 fl mice (Betz et al., 1998) with Ng2-
Cre BAC transgenic mice (Zhu et al.,
2008) to generate Ng2-Cre;gp130 fl/fl
mice, hereafter referred to as gp130	NG2
mice. The gp130	NG2 and control and the
gp130HetNG2 and Ng2-Cre littermates
were given injections of Ad-LIF and 4 d
later were given BrdU in the drinking wa-
ter 24 h before they were killed. We con-
firmed functional gp130 deletion within
the OL lineage of gp130	NG2 mice by im-
munostaining for pSTAT3 in Olig2/
CC1 OPCs (Fig. 5A,B). In LIF-treated
mice, pSTAT3 is detectable in 92.1 0.6%
of periventricular OPCs in control mice,
whereas in contrast, pSTAT3 is only de-
tectable in 24.3 3.4% of periventricular
Olig2/CC1 OPCs in gp130	NG2 mice
(mean SEM; n 3–4 per group). As we
have observed in wild-type mice, LIF
strongly induces OPC proliferation in
controlmice that retain one or both copies
of functional gp130; however, in
gp130	NG2mice, LIF-enhancedOPC pro-
liferation is severely reduced (Fig. 5C). It is
likely that ablation of gp130 inOPCs com-
pletely abolishes their proliferative response to LIF given that
cre-mediated recombination of gp130 floxed alleles seems to oc-
cur in 80% of adult OPCs. As an internal control, we also as-
sessed the LIF-induced proliferation of non-OL lineage cells. As
expected, in both gp130	NG2 and control mice, LIF strongly
stimulates the proliferation of Olig2-negative cells (Fig. 5D),
which are mostly microglia, demonstrating that the lack of
Olig2/BrdU cells in gp130	NG2 mice is not simply an artifact
arising from a reduced LIF response.
Figure 4. Myelin protein expression and node of Ranvier formation is enhanced by Ad-LIF treatment.Myelin protein (PLP) and
nodes of Ranvier were assessed in the CA3 stratum radiatum of the hippocampus. A–D, I, Ad-LIF restores expression of the
compactmyelinproteinPLPafter chronicdemyelination.A–D, Confocal projection imagesof immunostaining forPLP (purple) and
NF (green) are shown together and as individual monochrome images to the right of each dual color image. Compared withmice
maintained on a standard diet (A), PLP expression is reduced after 12 weeks of cuprizone feeding (B). Recovery of PLP expression
is limited 6weeks after injectionwith Ad-LacZ (C) comparedwithmice given injections of Ad-LIF (D). I, Quantification of the ratio
of the area of PLP signal above threshold over the area of NF signal above threshold. E–H, Confocal projection images show
immunostaining for Nav1.6 (red), Caspr (green), and Kv1.2 (blue). Expression/clustering of node-associated proteins is disrupted
by 12 week cuprizone exposure. E, F, Compare 12 week cuprizone (F ) to untreated (E). G, H, Ad-LIF treatment enhances the
restoration of Nav1.6 clustering surrounded by Caspr clustering at paranodes (arrowheads) compared with Ad-LacZ treatment. J,
Quantification of the number of Nav1.6
 nodes flanked on both sides by Caspr paranodes. ***p 0.001 between Ad-LIF- and
Ad-LacZ-treated groups. Scale bars, 20m.
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One additional caveat to using the Ng2-Cre BAC transgenic
line to ablate gp130 is that gp130 ablation would also be expected
to occur in OLs, which are derived from Ng2 cells, as well as
pericytes, which can express Ng2 (Ozerdem et al., 2001). How-
ever, by using the ROSA-YFP reporter line to assess the efficiency
of Cre recombination from the Ng2-Cre line, we find Cre-
mediated YFP expression in only 60.4  4.1% of CC1 OLs in
the dorsal forebrain and infrequently in pericytes (data not
shown), whereas YFP expression is detected in 88.3  5.3% of
adultNg2OPCs (mean SEM; n 2). Consistentwith this, we
observe LIF-induced pSTAT3 activation in many CC1 OLs in
gp130	NG2mice (Fig. 5B). In light of these findings, we think it is
unlikely that inactivation of gp130 from only a subset of mature
OLs or pericytes is responsible for the near-complete lack of LIF-
induced proliferation of OPCs in gp130	NG2 mice.
Discussion
Here we report that exogenous LIF delivery to the adult mouse
CNS can be used to enhance the endogenous progenitor cell re-
sponse and promote remyelination after cuprizone-induced de-
myelination. A key finding of this study is that exogenous LIF
stimulates OPC proliferation, as demonstrated by an increase in
BrdU incorporation in OPCs. This increase in proliferation is
observed both early (2–5 d) as well as 3 weeks after Ad-LIF deliv-
ery, indicating that the continuous release of LIF from
adenovirus-infected ependymal cells results in a sustained re-
sponse that expands the OPC population. Because LIF and other
gp130 cytokines enhance the survival of OL lineage cells in vivo
and in vitro, it is possible that the pro-survival effect of LIF also
contributes to the expansion of the OPC pool and subsequently
increased OL generation. Indeed, sustained LIF exposure seems
to support the survival of supraphysiological numbers of Olig2,
OL lineage cells (Fig. 1G,H), most notably in regions adjacent to
the ventricles where LIF levels are presumably the highest. There-
fore, LIF not only stimulates OPC proliferation but may further
support the expansion of OL lineage cells by enhancing their
survival.
The finding that LIF expands the population of prelabeled
YFP OPCs in PDGFRa-CreER;ROSA-YFP mice also strongly
suggests that LIF mediates this expansion by acting primarily
upon pre-existing, parenchymal OPCs rather than by enhancing
the production of new OPCs from SVZ progenitors, since fate
tracing in these mice specifically labels OPCs and their progeny
but does not label SVZNSCs (Rivers et al., 2008). This conclusion
is also supported by our previous experiment showing that these
proliferating parenchymal progenitors were not labeled by the
injection of a GFP-encoding retrovirus into the SVZ (Bauer and
Patterson, 2006). Given that OPCs are very abundant and widely
disseminated throughout the CNS, they represent an ideal target
population for therapeutic approaches aimed at promoting the
generation of new OLs.
Our finding that ablation of gp130 in OL lineage cells dramat-
ically reduces their proliferative response to LIF suggests that LIF
stimulates their proliferation directly. Alternatively, LIF might
stimulate OPCs by inducing the expression of additional gp130
cytokines. Regardless, we demonstrate that activation of gp130
signalingwithinOPCs is necessary for their proliferative response
to exogenous LIF. Thus, gp130 cytokine-based strategies aimed at
promoting myelin repair would require direct action on OPCs.
Whether this can be achieved without direct delivery to the CNS
requires further study. LIF can cross the blood–brain barrier
through a saturable transportmechanism (Pan et al., 2000) that is
enhanced by neuroinflammation (Pan et al., 2008), raising the
possibility that systemically delivered LIF may be sufficient to
mediate the effects on OPCs, especially at sites of inflammatory
demyelination. Indeed, Butzkueven et al. (2002) were able to
detect systemically injected LIF in the CNS of mice with experi-
mental autoimmune encephalomyelitis (EAE) but not in non-
EAE controls. Notably, daily systemic LIF administration did not
increase the number of Ng2 OPCs in the CC after 4 weeks of
cuprizone (Marriott et al., 2008), a finding that might be ex-
plained by the lack of a direct effect of systemically delivered LIF
on OPCs, or by the dramatic, spontaneous increase in OPCs that
is present after 4 weeks of cuprizone treatment, which may have
masked an effect of LIF on OPC expansion.
Interestingly, inactivation of gp130 in the OL lineage does not
affect the basal rate ofOPCproliferation in controlmice, suggest-
ing that endogenous gp130 cytokine signaling does not contrib-
ute substantially to the rate of cycling of these cells under normal
physiological conditions. Likewise, neither gp130	NG2 mice nor
Nes-Cre;gp130 fl/fl mice, in which gp130 signaling is ablated
embryonically in nearly all neural cells, has an obvious postnatal
Figure 5. Stimulation of OPC proliferation by exogenous LIF is reduced by deletion of gp130
in the OL lineage. Six-week-old gp130	NG2 (Ng2-Cre;gp130 fl/fl) and control, gp130 Het NG2
(Ng2-Cre;gp130 fl/wt), and Ng2-Cre (gp130 fl/fl or gp130 fl/wt) littermates were given injec-
tionsof eitherAd-LIForAd-lacZand4d laterweregivenBrdU in their drinkingwater for the final
24 h before they were killed. A, B, The majority of Olig2/CC1 OPCs in gp130	NG2 mice no
longer activate STAT3 in response to LIF treatment, as demonstrated by immunostaining for
pSTAT3 (red), Olig2 (blue), and CC1 (green). Numbered dashed boxes in A and B are enlarged
below each image and separated into red (pSTAT3) and green/blue (CC1/Olig2) channels to
demonstrate colocalization of pSTAT3nucleiwith Olig2/CC1 cellsmarkedwith asterisks.
C, D, Olig2 and Brdu cells were counted in confocal images taken of the fimbria. C, The
graph shows the number of Olig2/BrdU cells/mm2. D, The graph shows the number of
Olig2-negative, BrdU cells/mm2. The gp130 HetNG2 and Ng2-Cre mice were combined in
the Ad-LIF and Ad-lacZ control groups. n 3–6mice per group. In C, ***p 0.001 compared
with all other groups; #Not significantly different from Ad-LacZ-treated groups. In D, ***p
0.001 between Ad-LIF and Ad-LacZ, regardless of genotype. Scale bar, 20m.
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hypomyelination phenotype (B. E. Deverman, unpublished
data). These findings imply that the loss of gp130 signaling, either
specifically in OL lineage cells or in all neural cells, does not have
significant consequences for developmental myelination. Given
that both LIF and CNTF knock-outs have delayed OL generation
in the optic nerve (Barres et al., 1996; Ishibashi et al., 2009), the
loss of these cytokines may affect the timing of OL development
indirectly. Whether endogenous LIF and/or other gp130 cyto-
kines contribute to the enhancement of OPC proliferation that
occurs in response to pathological demyelination is not clear. In
support of this possibility, compared with wild-type mice, OPC
proliferation is reduced in Cntf/mice late during the course of
EAE (Linker et al., 2002). In contrast, the spontaneous expansion
of OPCs that occurs by 4 weeks of cuprizone treatment is not
influenced by the loss of LIF (Marriott et al., 2008).
Our finding that sustained exogenous LIF expression en-
hances bothOPCproliferation and the generation ofmyelinating
OLs is consistent with in vitro studies but is surprising when
considered in the context of studies of other factors such as PDGF
and FGF2, which enhance OPC proliferation at the expense of
differentiation (Goddard et al., 2001; Armstrong et al., 2002,
2006; Woodruff et al., 2004). How LIF stimulates both OPC pro-
liferation andOL differentiation is unclear. Since LIF, like CNTF,
is notmitogenic forOPCs per se, but only expands the number of
OPCs in the presence of PDGF (Barres et al., 1996), one hypoth-
esis is that LIF-induced gp130 signaling may “activate” OPCs,
thereby enhancing both their response tomitogens when present
and to differentiation signals, such as those from demyelinated
axons, when mitogens become limiting. Alternatively, LIF may
promoteOLdifferentiation indirectly by increasing the density of
OPCs, which is known to promote their differentiation, at least
when seeded on dorsal root ganglion neurons in culture (Rosen-
berg et al., 2008), or through an intrinsic timer mechanism that
may limit the number of OPC divisions that can occur before the
OPCs differentiate (Temple and Raff, 1986; Dugas et al., 2007).
Regardless of the mechanism, we demonstrate that exogenous
LIF delivery can be used to stimulate the otherwise essentially
dormant OPC population to proliferate and generate new OLs
that contribute to remyelination. Importantly, these beneficial
effects of LIF onOL generation and remyelination cannot simply
be attributed to the well described, pro-survival action of LIF on
OLs since we delivered LIF to cuprizone-treated mice at a time
when mature OLs are severely depleted.
The need for remyelination-enhancing therapeutics is great.
Significant progress toward developing such therapies has been
made by injecting exogenous progenitors, from a variety of
sources that are capable of generating myelinating OLs. Progen-
itor transplantation seems especially promising for the treatment
of the congenital hypomyelinating diseases (Windrem et al.,
2008) and localized traumatic injury (Cao et al., 2005; Keirstead
et al., 2005; Lowry et al., 2008), but its efficacy for inducing re-
myelination in adult demyelinating disorders with disseminated
lesions such as MS is less certain. For these disorders, enhancing
repair by stimulating OL generation from endogenous progeni-
tor cells is an attractive option.However, progress demonstrating
the efficacy of targeting endogenousOPCs andNSCs with factors
to promote remyelination has been slow, with only a few factors
showing therapeutic promise (Warrington et al., 2007; Harsan et
al., 2008). This is attributable only in part to our incomplete
understanding of the factors that influence OL lineage cells and
remyelination in vivo. Progress has also been hindered by chal-
lenges associatedwith available animalmodels,most of which are
poorly suited for demonstrating the efficacy of, and mechanism
behind, any potential remyelination-promoting agents. This is
primarily because of the relative efficiency of remyelination in
rodents. Indeed, even after a 12 week course of cuprizone treat-
ment, which has been reported to induce a chronic state of de-
myelination, we observe significant spontaneous remyelination
in themedial CC, whichmasks any increase in remyelination that
may occur in response to Ad-LIF treatment. We therefore fo-
cused our study on the hippocampus, where the spontaneous
remyelination of axons within several layers is incomplete.
In MS, the widespread incidence of GM demyelination
(Brownell and Hughes, 1962; Kidd et al., 1999; Bø et al., 2003;
Geurts et al., 2005) and abnormalities (Rovaris et al., 2000; Ge et
al., 2002; Vrenken et al., 2006) is now broadly appreciated, and
GMchanges correlate with the cognitive impairment that is com-
mon in MS patients (Rovaris et al., 2000; Vrenken et al., 2006;
Amato et al., 2007). GM lesions are present throughout the cortex
and hippocampus (Pirko et al., 2007; Geurts et al., 2008). Indeed,
demyelinated hippocampal lesions were found in 15 of 19 MS
cases (Geurts et al., 2007), and hippocampal lesions were seen in
14 of 16 randomly selected, relapse-remitting (RR) and second-
ary progressive (SP) patients (Roosendaal et al., 2008). In addi-
tion, hippocampal atrophy that exceeds global brain atrophy was
observed in RR and SP patients, and this atrophy correlated with
declining performance on a word-list learning task (Sicotte et al.,
2008). Thus, cuprizone-induced demyelination of the hip-
pocampus is an attractivemodel of GMdemyelination and remy-
elination, which has not been well characterized in other animal
models.
In summary, we find that exogenous delivery of the neuropoi-
etic cytokine LIF to the CNS stimulates the proliferation of pa-
renchymal OPCs. LIF-induced OPC proliferation is dramatically
reduced when gp130 is ablated from the OL lineage, suggesting
that their proliferation requires LIF-induced gp130 signaling in
these cells. Importantly, the effect of LIF on OPC proliferation
can be harnessed to restore the number of mature OLs, enhance
myelin protein expression, and reform nodes of Ranvier in the
chronically demyelinated hippocampus of cuprizone-treated
mice. Thus, LIF has repair-promoting activities that could be
beneficial for disorders and injuries in which demyelination con-
tributes to ongoing disability. Together with previous studies
showing that LIF can ameliorate EAE (Butzkueven et al., 2002;
Slaets et al., 2010; Cao et al., 2011) and improve OL survival and
motor symptoms after spinal cord injury (Zang and Cheema,
2003; Kerr and Patterson, 2005), our findings should reinforce
interest in the further exploration of LIF, and other gp130 cyto-
kines, as therapeutic agents for demyelinating disorders.
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